Shopping Cart
Remove All
Your shopping cart is currently empty
KYN-101 is an orally active and selective aryl hydrocarbon receptor (AHR) inhibitor with anticancer activity. KYN-101 decreases CYP1A1 mRNA expression and can be used in the study of breast cancer and acute myeloid leukemia. KYN-101 is an orally active and selective aryl hydrocarbon receptor (AHR) inhibitor with anticancer activity.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $61 | - | In Stock | |
| 5 mg | $147 | In Stock | In Stock | |
| 10 mg | $228 | In Stock | In Stock | |
| 25 mg | $428 | - | In Stock | |
| 50 mg | $662 | - | In Stock | |
| 100 mg | $993 | - | In Stock |
| Description | KYN-101 is an orally active and selective aryl hydrocarbon receptor (AHR) inhibitor with anticancer activity. KYN-101 decreases CYP1A1 mRNA expression and can be used in the study of breast cancer and acute myeloid leukemia. KYN-101 is an orally active and selective aryl hydrocarbon receptor (AHR) inhibitor with anticancer activity. |
| In vivo | KYN-101 (10 mg/kg; once daily for 12 days; oral administration) treatment in 6-8-week-old C57BL/6J mice (B16IDO tumor-bearing mice) significantly reduced tumor growth. Additionally, the combination of KYN-101 and anti-PD-1 antibody further delayed tumor growth and extended survival in CT26 models[1]. |
| Synonyms | KYN101, KYN 101 |
| Molecular Weight | 386.43 |
| Formula | C22H19FN6 |
| Cas No. | 2247950-73-6 |
| Smiles | FC1=CN=CC(=C1)C2=NC3=C(C=NN3C(=C2)NCCC4=CNC=5C=CC=CC54)C |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 80 mg/mL (207.03 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.